Latham & Watkins has advised Novo Holdings as the co-lead investor in the Series E Preferred Stock financing round for Quanta Dialysis Technologies, a leader in transforming kidney care through its award-winning Quanta™ Dialysis System, raising more than US$60 million of additional capital.
Led by Novo Holdings, Glenview Capital, and b2venture, with broad participation by existing shareholders, the latest funding round underscores strong investor confidence in Quanta’s market potential to revolutionize the treatment of kidney disease across a variety of settings. With the newly secured capital, Quanta will expand its commercial presence in the US and continue to invest in cutting-edge innovation within the sector.
The Latham team was led by London corporate partner Robbie McLaren, with associates Samantha Peacock and Richard Dodding.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
